The global COPD therapeutics market is expected to grow at a CAGR of XX% during the forecast period 2016-2021. The market was estimated to be USD XX million in 2015 and is forecasted to reach USD XX million by 2021.
The growth of the global chronic obstructive pulmonary disease (COPD) market is expected to be fueled by a high number of new, more efficacious and convenient products entering the market and commanding a greater value compared to the therapies already existing in the market. Another major factor propelling the growth of the market is the introduction of novel innovations like ultrasonic nebulizers, which are superior to the existing jet nebulizers. The competitive environment is expected to intensify with an increase in product extensions, technological innovations, and an increase in the number of mergers and acquisitions. The market for COPD drugs shows potential opportunity in both developed and developing countries. Due to the effectiveness and advancements in technology, many companies are focusing and collaborating to develop innovative COPD drugs and treatments.
Global COPD Therapeutics - Market Dynamics
The report details several factors driving and restraining the market, some of which are discussed below.
The global COPD therapeutics market has been segmented by drug type and products. By drugs, the market is segmented into Short-Acting Bronchodilators, Corticosteroids, Methylxanthines, Long-Acting Bronchodilators and Phosphodiesterase-4 Inhibitors). The products segment consists of inhalers (MDI’s. DPI’s and SMI’s) and nebulizers (jet nebulizers, ultrasonic nebulizers). The market has been geographically segmented into North America, Europe, Asia-Pacific, and Rest of the World.
Some of the key players in the market are:
What the Report Offers